By Abigail Townsend
Date: Tuesday 10 Feb 2026
(Sharecast News) - AstraZeneca posted a spike in full-year revenues and earnings on Tuesday, boosted by strong demand for its cancer drugs, and forecast further growth in the current year.
| Final Results | 10-Feb-2026 | 07:00 | RNS |
| Update on Saphnelo subcutaneous administration | 03-Feb-2026 | 07:00 | RNS |
| Total Voting Rights | 02-Feb-2026 | 15:00 | RNS |
| Imfinzi recommended in EU for early gastric cancer | 02-Feb-2026 | 07:05 | RNS |
| AstraZeneca begins trading on NYSE | 02-Feb-2026 | 07:00 | RNS |
| Questor :AstraZeneca | 29-Apr-2014 | Telegraph |
| Questor : AstraZeneca | 24-Jan-2014 | Telegraph |
| Questor:AstraZeneca | 22-Dec-2011 | Telegraph |
| Investment Column:AstraZeneca | 28-Oct-2011 | The Independent |
| Investment Column: AstraZeneca | 23-Jun-2011 | The Independent |
| Currency | UK Pounds |
| Share Price | 15,030.00p |
| Change Today | 124.00p |
| % Change | 0.83 % |
| 52 Week High | 15,064.00 |
| 52 Week Low | 9,667.00 |
| Volume | 346,603 |
| Shares Issued | 1,550.94m |
| Market Cap | £233,107m |
| Beta | 0.86 |
| RiskGrade | 123 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Strong Buy | 10 |
| Buy | 13 |
| Neutral | 3 |
| Sell | 0 |
| Strong Sell | 1 |
| Total | 27 |

| Latest | Previous | |
|---|---|---|
| 2nd Interim | 1st Interim | |
| Ex-Div | 19-Feb-26 | 07-Aug-25 |
| Paid | 23-Mar-26 | 08-Sep-25 |
| Amount | 217.00¢ | 103.00¢ |
| Time | Volume / Share Price |
| 10:06 | 2 @ 15,029.15p |
| 10:06 | 0 @ 15,028.00p |
| 10:06 | 0 @ 15,028.00p |
| 10:06 | 0 @ 15,028.00p |
| 10:06 | 15 @ 15,030.00p |
You are here: research